Immuneering Corporation

Immuneering Corporation is a clinical-stage oncology company headquartered in Cambridge, Massachusetts. Its mission is to improve patient outcomes across oncologic and neurologic diseases, specifically by enabling cancer patients to live longer without compromising their quality of life during treatment. The company aims to translate cutting-edge scientific discoveries into transformative therapies.

Immuneering is focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors (DCIs). Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to target MAPK pathway-driven cancers, including pancreatic cancer and non-small cell lung cancer (NSCLC) with RAS or RAF mutations. The company's pipeline also includes IMM-6-415 (envometinib) for solid tumors and other early-stage discovery programs. Additionally, Immuneering provides computational biology capabilities to other pharmaceutical and biotechnology companies.

Led by Co-Founder and CEO Ben Zeskind, with Thomas J. Schall appointed Chairman of the Board in September 2025, Immuneering is actively advancing atebimetinib. The company has achieved FDA and EMA alignment for a pivotal Phase 3 trial of atebimetinib in first-line pancreatic cancer and has reported positive survival data from its Phase 2a trials in this indication. Immuneering is also planning combination studies for atebimetinib in lung cancer. In November 2025, Immuneering was added to the Nasdaq Biotechnology Index.